McCarthy Sean A. sold CTMX

November 6, 2025 · Form 4 insider transaction

McCarthy Sean A. sold 101,793 shares of CytomX Therapeutics, Inc. at $4.54 per share, a transaction worth $461.9K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 344 days after the transaction.

Direction
Disposed (sell-side)
Shares
101,793
Price
$4.54
Total value
$461.9K
RoleOfficer, Director
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateNovember 6, 2025
Filing dateOctober 16, 2026
Shares owned after1,089,684
OwnershipDirect
10b5-1 planYes
AmendedYes

Footnotes

The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024.; This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.; This Form 4/A restates in its entirety the original Form 4 filed on 11/10/2025 (the "Original Form 4") to report an inadvertently omitted exercise that was part of a same-day exercise-and-sale transaction; the sale was timely reported in the Original Form 4. Due to the omission, the Original Form 4 understated the Reporting Person's direct holdings following the reported transactions by 101,793 shares, and this understatement carried forward into Column 5 of Table I of the Reporting Person's Forms 4 filed on 2/4/2026 and 3/19/2026 (the "Subsequent Reports"). The direct holdings reported in Column 5 of Table I of this Form 4/A have been corrected. The Subsequent Reports are not being amended; the direct holdings amounts reported therein should each be read as increased by 101,793 shares.; Includes 488,750 restricted stock units.

View the original Form 4 on SEC EDGAR